PUBLISHER: Transparency Market Research | PRODUCT CODE: 1178054
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1178054
NAMPT Inhibitors Pipeline Analysis (Phase: Phase II, Phase I/II, Phase I, and Preclinical; and Type of Molecule: Small Molecules and Biologics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
TMR's report on the global NAMPT inhibitors pipeline analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global NAMPT inhibitors pipeline analysis market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global NAMPT inhibitors pipeline analysis market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the NAMPT inhibitors pipeline analysis market.
The report delves into the competitive landscape of the global NAMPT inhibitors pipeline analysis market. Key players operating in the global NAMPT inhibitors pipeline analysis market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global NAMPT inhibitors pipeline analysis market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global NAMPT Inhibitors Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Phase Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
5. Key Insights
- 5.1. Overview on Kay players operating in the market space
- 5.2. Key industry events (mergers, acquisitions, partnerships, etc.)
- 5.3. COVID-19 pandemic impact on industry
6. North America NAMPT Inhibitors Market Analysis and Forecast
- 6.1. Introduction
- 6.1.1. Key Findings
- 6.2. Market Analysis, by Phase, 2017 - 2031
- 6.2.1. Phase II
- 6.2.2. Phase I/II
- 6.2.3. Phase I
- 6.2.4. Preclinical
- 6.3. Market Analysis, by Application, 2017 - 2031
- 6.3.1. Oncology
- 6.3.2. Others (respiratory and neurology disorders)
- 6.4. Market Analysis, by Type of Molecule, 2017 - 2031
- 6.4.1. Small Molecules
- 6.4.2. Biologics
7. Europe NAMPT Inhibitors Market Analysis and Forecast
- 7.1. Introduction
- 7.1.1. Key Findings
- 7.2. Market Analysis, by Phase, 2017 - 2031
- 7.2.1. Phase II
- 7.2.2. Phase I/II
- 7.2.3. Phase I
- 7.2.4. Preclinical
- 7.3. Market Analysis, by Application, 2017 - 2031
- 7.3.1. Oncology
- 7.3.2. Others (Respiratory and Neurology Disorders)
- 7.4. Market Analysis, by Type of Molecule, 2017 - 2031
- 7.4.1. Small Molecules
- 7.4.2. Biologics
8. Rest of the World NAMPT Inhibitors Market Analysis and Forecast
- 8.1. Introduction
- 8.1.1. Key Findings
- 8.2. Market Analysis, by Phase, 2017 - 2031
- 8.2.1. Phase II
- 8.2.2. Phase I/II
- 8.2.3. Phase I
- 8.2.4. Preclinical
- 8.3. Market Analysis, by Application, 2017 - 2031
- 8.3.1. Oncology
- 8.3.2. Others (Respiratory and Neurology Disorders)
- 8.4. Market Analysis, by Type of Molecule, 2017 - 2031
- 8.4.1. Small Molecules
- 8.4.2. Biologics
9. Competition Landscape
- 9.1. Market Player - Competition Matrix (by tier and size of companies)
- 9.2. Company Profiles
- 9.2.1. Onxeo
- 9.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 9.2.1.2. Product Portfolio
- 9.2.1.3. SWOT Analysis
- 9.2.1.4. Strategic Overview
- 9.2.2. Aqualung Therapeutics
- 9.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 9.2.2.2. Product Portfolio
- 9.2.2.3. SWOT Analysis
- 9.2.2.4. Strategic Overview
- 9.2.3. Antengene Corporation
- 9.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 9.2.3.2. Product Portfolio
- 9.2.3.3. SWOT Analysis
- 9.2.3.4. Strategic Overview
- 9.2.4. OncoTartis, Inc.
- 9.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 9.2.4.2. Product Portfolio
- 9.2.4.3. SWOT Analysis
- 9.2.4.4. Strategic Overview
- 9.2.5. Karyopharm Therapeutics
- 9.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 9.2.5.2. Product Portfolio
- 9.2.5.3. SWOT Analysis
- 9.2.5.4. Strategic Overview
- 9.2.1. Onxeo
